Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

References

• BenchimolEIFortinskyKJGozdyraPVan den HeuvelMVan LimbergenJGriffithsAMEpidemiology of pediatric inflammatory bowel disease: a systematic review of international trendsInflamm Bowel Dis201117142343920564651
   PubMed Web of Science ®Google Scholar
• MarkowitzJHyamsJMackDCorticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s diseaseClin Gastroenterol Hepatol2006491124112916861053
   PubMed Web of Science ®Google Scholar
• RuemmeleFMVeresGKolhoKLConsensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s diseaseJ Crohns Colitis20148101179120724909831
   PubMed Web of Science ®Google Scholar
• HyamsJSMarkowitzJWyllieRUse of infliximab in the treatment of Crohn’s disease in children and adolescentsJ Pediatr2000137219219610931411
   PubMed Web of Science ®Google Scholar
• TurnerDGrossmanABRoshJMethotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s diseaseAm J Gastroenterol2007102122804281218042110
   PubMed Web of Science ®Google Scholar
• BarabinoATorrenteFVenturaACucchiaraSCastroMBarberaCAzathioprine in paediatric inflammatory bowel disease: an Italian multicentre surveyAliment Pharmacol Ther20021661125113012030954
   PubMed Web of Science ®Google Scholar
• HyamsJCrandallWKugathasanSInduction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in childrenGastroenterology2007132386387317324398
   PubMed Web of Science ®Google Scholar
• HanauerSBWagnerCLBalaMIncidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s diseaseClin Gastroenterol Hepatol20042754255315224278
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
   PubMed Web of Science ®Google Scholar
• HyamsJSLererTGriffithsALong-term outcome of maintenance infliximab therapy in children with Crohn’s diseaseInflamm Bowel Dis200915681682219107783
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology2006130232333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut20075691232123917299059
   PubMed Web of Science ®Google Scholar
• Martín-de-CarpiJPocielloNVareaVLong-term efficacy of adalimumab in paediatric Crohn’s disease patients naïve to other anti-TNF therapiesJ Crohns Colitis20104559459821122566
   PubMed Web of Science ®Google Scholar
• HoGTSmithLAitkenSThe use of adalimumab in the management of refractory Crohn’s diseaseAliment Pharmacol Ther200827430831518081730
   PubMed Web of Science ®Google Scholar
• ViolaFCivitelliFDi NardoGEfficacy of adalimumab in moderate-to-severe pediatric Crohn’s diseaseAm J Gastroenterol2009104102566257119550415
   PubMed Web of Science ®Google Scholar
• RoshJRLererTMarkowitzJRetrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s diseaseAm J Gastroenterol2009104123042304919724267
   PubMed Web of Science ®Google Scholar
• LevineAKoletzkoSTurnerDESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescentsJ Pediatr Gastroenterol Nutr201458679580624231644
   PubMed Web of Science ®Google Scholar
• LevineAGriffithsAMarkowitzJPediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classificationInflamm Bowel Dis20111761314132121560194
   PubMed Web of Science ®Google Scholar
• NoeJDPfefferkornMShort-term response to adalimumab in childhood inflammatory bowel diseaseInflamm Bowel Dis200814121683168718618629
   PubMed Web of Science ®Google Scholar
• WyneskiMJGreenAKayMWyllieRMahajanLSafety and efficacy of adalimumab in pediatric patients with Crohn diseaseJ Pediatr Gastroenterol Nutr2008471192518607264
   PubMed Web of Science ®Google Scholar
• FumeryMJacobASarterHEfficacy and safety of adalimumab after infliximab failure in pediatric Crohn diseaseJ Pediatr Gastroenterol Nutr201560674474826000887
   PubMed Web of Science ®Google Scholar
• PappKAFonjallazPCasset-SemanazFKruegerJGMittkowskiKMApproaches to reporting long-term dataCurr Med Res Opin2008242001200818534049
   PubMed Web of Science ®Google Scholar
• HyamsJSGriffithsAMarkowitzJSafety and efficacy of adalimumab for moderate to severe Crohn’s disease in childrenGastroenterology2012143236537422562021
   PubMed Web of Science ®Google Scholar
• RussellRKWilsonMLLoganathanSA British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel diseaseAliment Pharmacol Ther201133894695321342211
   PubMed Web of Science ®Google Scholar
• CozijnsenMDuifVKokkeFAdalimumab therapy in children with Crohn disease previously treated with infliximabJ Pediatr Gastroenterol Nutr201560220521025286063
   PubMed Web of Science ®Google Scholar
• DziechciarzPHorvathAKierkuśJEfficacy and Safety of Adalimumab for Paediatric Crohn’s Disease: A Systematic ReviewJ Crohns Colitis201610101237124426995184
   PubMed Web of Science ®Google Scholar
• WilliamsCJPeyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumor necrosis factor α therapy in inflammatory bowel diseaseAliment Pharmacol Ther201439544745824444171
   PubMed Web of Science ®Google Scholar
• SchreiberSReinsichRColombelJEarly Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARMGastroenterology2007132A-147
   Web of Science ®Google Scholar
• Peyrin-BirouletLDeltenrePde SurayNBrancheJSandbornWJColombelJFEfficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trialsClin Gastroenterol Hepatol20086664465318550004
   PubMed Web of Science ®Google Scholar
• LichtensteinGRRutgeertsPSandbornWJA pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel diseaseAm J Gastroenterol201210771051106322613901
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registryAm J Gastroenterol201210791409142222890223
   PubMed Web of Science ®Google Scholar
• DeepakPStobaughDJEhrenpreisEDInfectious complications of TNF- alfa inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the food and drug administration adverse event reporting systemJ. Gastroenterol Liver Dis2013223269276
   Web of Science ®Google Scholar
• D’HaensGVermeireSLambrechtGIncreasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s diseaseGastroenterology201815451343135129317275
   PubMed Web of Science ®Google Scholar